<DOC>
	<DOC>NCT01537692</DOC>
	<brief_summary>The purpose of this study is to compare the systemic levels of beclomethasone 17 monopropionate (17 BMP - the active metabolite of BDP) after intranasal administration of BDP HFA with the systemic levels of 17 BMP after administration of orally inhaled BDP HFA in healthy volunteers.</brief_summary>
	<brief_title>Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Informed Consent Male or female subjects 1845 years of age General good health History of physical findings of nasal pathology (within 60 days prior to Screening Visit) Participation in any investigational drug study 30 days preceding Screening Visit History of respiratory infection/disorder with 28 days preceding Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>